Cleo Diagnostics is challenging the status quo by making earlier detection of ovarian cancer a reality
About CleoDX
Executive Summary
Incorporated on 30 November 2021, Cleo Diagnostics (CleoDX) is a biotechnology company which was specifically formed to commercialize novel technology for the detection of ovarian cancers.
The technology underlying the Company’s lead product was discovered and developed at the Hudson Institute of Medical Research in Melbourne, Australia.
Arising from a flagship cancer biomarker discovery program it is the culmination of over 15 years of intense scientific research.
The Company was listed on the ASX on 22 August 2023 to provide a public platform to raise capital and accelerate the development and commercialisation of a suite of ovarian cancer related tests.
Cleo’s Mission
Under the scientific direction of Cleo’s Chief Scientist; Dr Andrew Stephens, Cleo Diagnostics is developing a portfolio of tests based on the same underlying technology.
The technology consists of antibodies that bind to select biomarkers identified by Dr Stephens and his team as being indicative of the presence of ovarian cancer.
The biomarkers can be detected in a patient’s blood meaning that the test is:
• Minimally-invasive
• Low-cost
• Adaptable for deployment across multiple testing environments
Only about 20% of ovarian cancers are found at an early stage. When ovarian cancer is found early, about 94% of patients live longer than 5 years after diagnosis. When looking at all stages, the current 5-year survival is only 45%.
Early cancers of the ovaries often cause no symptoms. Symptoms of ovarian cancer can also be caused by other, less serious conditions. By the time ovarian cancer is considered as a possible cause of these symptoms, it usually has already spread.
Screening tests and exams are used to detect a disease, like cancer, in people who don’t have any symptoms. (For example, a mammogram can often detect breast cancer in its earliest stage, even before a doctor can feel the cancer.)
There has been a lot of research to develop a screening test for ovarian cancer, but there hasn’t been much success so far.
Cleo Diagnostics aims to break the status quo and set new standards for cancer detection.
